by Paul Tracy, editor High Yield International
Last year, Paris-based pharmaceutical giant Sanofi-Aventis (SNY) faced a problem many large pharmaceutical firms have encountered in recent years: a raft of major patent expirations.
Now, however, growth from Sanofi's pipeline of new drugs is beginning to power growth.
Market News and Data brought to you by Benzinga APIsLast year, Paris-based pharmaceutical giant Sanofi-Aventis (SNY) faced a problem many large pharmaceutical firms have encountered in recent years: a raft of major patent expirations.
Now, however, growth from Sanofi's pipeline of new drugs is beginning to power growth.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Health CarePharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in